Clinical Research Management (ClinicalRM), a full-service CRO providing support for basic and applied research, clinical trials and regulatory support, has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA). With this contract award, ClinicalRM becomes part of a clinical studies network being established by BARDA to support development of vaccines, drugs and diagnostics, known as medical countermeasures, needed to protect health and potentially save lives in public health emergencies. The network will provide clinical services in support of adequate and well-controlled phase I through IV clinical trials or trials during a public health emergency, and will support the evaluation of chemical, biological, radiological, nuclear, pandemic influenza and emerging infectious disease medical countermeasures.

ClinicalRM is one of only five other companies to be awarded this contract, which includes a two-year contract with three one-year option BARDA may exercise. Total costs of the program will be financed with federal money. The total contract ceiling for the five-year program is $100 million.